Uses a special CT scan to track kidney cancer response to first treatments
Studies a special CT scan to monitor adults with spread kidney cancer on first treatments.
Plain-language title generated from the registry record
Registry title: Dual-energy SPEctral CT to Evaluate Response to First-line Therapies in Patients With Metastatic Clear Cell REnal Cancer
Key facts
- Where
- Bologna, ItalySee the 2 sites
Where in Italy
- Irccs Azienda Ospedaliero - Universitario Di BolognaBologna, ItalyTaking people
- Oncology Unit, IRCCS Azienda Ospedaliero Universitaria BolognaBologna, ItalyTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- IRCCS Azienda Ospedaliero-Universitaria di Bologna
- Trial code
- NCT06863857
- Record updated
- 7 March 2025
- Original description
To evaluate the utility of dual-energy spectral computed tomography (CT) scan in monitoring treatment in patients with metastatic clear cell carcinoma of the kidney. In particular, to analyze the use of spectral CT in patients who are candidates to receive first-line treatment based on combinations of immunotherapy and molecularly targeted drugs. In particular, the parameters derived from the use of this technology and their variation during therapy will be analyzed together with some possible molecular alterations highlighted by the analysis of the tumor tissue previously taken from the patient, relating them to the response to first-line therapy with immuno-combinations.Read full original descriptionShow less
Dual-energy SPEctral CT to Evaluate Response to New First-line Therapies in Patients With Metastatic Clear Cell REnal Cancer and the Association of Its Parameters With Molecular Alterations
To evaluate the utility of dual-energy spectral computed tomography (CT) scan in monitoring treatment in patients with metastatic clear cell carcinoma of the kidney. In particular, to analyze the use of spectral CT in patients who are candidates to receive first-line treatment based on combinations of immunotherapy and molecularly targeted drugs. In particular, the parameters derived from the use of this technology and their variation during therapy will be analyzed together with some possible molecular alterations highlighted by the analysis of the tumor tissue previously taken from the patient, relating them to the response to first-line therapy with immuno-combinations.
Inclusion: Age ≥ 18 years; Patients with histological or cytological diagnosis of clear cell RCC; Patients with metastatic disease documented by imaging or biopsy of the secondary site; Patients who have not had previous treatment for RCC; Patients with an indication for first-line medical treatment based on IO+TKI, IO+IO as per clinical practice at the Medical Oncology Unit of the IRCCS University Hospital of Bologna; Patients who have already had a dual-energy spectral total-body CT with MDC within 4 weeks of treatment initiation; Availability of a formalin-fixed, paraffin-embedded histological block (FFPE) stored for a period <15 years, for the execution of molecular analysis for the search for alterations of the genes ATM, BAP1, KDM5C, MET, MTOR, NF2, PBRM1, PIK3CA, PTEN, SETD2, SMARCB1, TP53, TSC1, TSC2, VHL; Patients who knowingly express consent to participate in the study after signing the consent.
Exclusion: -None.